CD6

Across TCGA pan-cancer cohorts, CD6 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of CD6’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD6 is over-expressed in tumor, although a few such as LUSC and CHOL show the opposite, repressed pattern.

KIRC, STAD, and LUSC are the cancer types where CD6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.717	<.001	11	view →
STAD	All	II,III,IV	+1.234	.001	7	view →
LUSC	All	All	−0.653	<.001	7	view →
BRCA	All	All	+0.416	<.001	4	view →
CHOL	All	II,III,IV	−0.710	.049	2	view →
KIRP	All	All	+0.695	.002	2	view →
UCEC	All	All	−0.518	.017	2	view →
ESCA	All	All	+0.921	.022	1	view →
LIHC	Female	II,III,IV	+0.478	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

CD6–KIRC

Open the KIRC breakdown →